Bill Breen is a Senior Advisor to Balmoral Advisors, working with clients primarily in the Chemicals and Materials industry. Bill approximately 50 years of experience as an executive and M&A advisor to specialty chemicals companies, completing his first M&A transaction in 1974 for a Fortune 200 company. Bill was responsible for acquisitions totaling approximately half of the $1 billion chemical business now known as Ingevity (NYSE: NGVT). Bill took the company’s Custom Chemicals unit private in 1997 after 23 years of corporate ownership, and as President bolted on a complementary business, then merged it with ArrMaz, creating an entity which sold for $570 million in 2019. Since 2003, Bill has advised chemicals clients on buyside and sellside M&A deals in the $10-500 million transaction value range.
Bill has a BA and BChE in Chemical Engineering and Economics from the University of Delaware and an MBA in Marketing & Finance from the Wharton School of Business at the University of Pennsylvania.